TD Cowen downgraded Standard BioTools (LAB) to Hold from Buy with a price target of $1.55, down from $1.60, post the Q2 report. The company sees a lower growth outlook for the core business and less visibility following the sale of SomaLogic. The company’s core business trends will continue to be challenged amid macro headwinds, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LAB:
- Hold Rating for Standard BioTools Amid Uncertainty Following SomaLogic Sale and Market Challenges
- Standard BioTools Delays Quarterly Report Filing
- Standard BioTools Reports Q2 2025 Financial Results
- Standard BioTools Announces SomaLogic Sale to Illumina
- Standard BioTools reports Q2 EPS (9c), consensus (4c)